Leadership

Meet Our Team

At ViewRay, our vision is clear – we’re dedicated to conquering
cancer by re-envisioning radiation therapy. Meet ViewRay’s leadership team committed
to innovation excellence.

Scott Drake

President and Chief Executive Officer

Scott W. Drake has served as our President and Chief Executive Officer and as a member of our board of directors since July 2018. Mr. Drake has over 30 years of experience in the medical device field. From August 2011 to August 2017, he served as President and Chief Executive Officer, and as a member of the board of directors of The Spectranetics Corporation (NASDAQ: SPNC), a medical device company. From November 2009 to July 2011, he was a Senior Vice President of DaVita Corporation (NYSE: DVA), a provider of kidney care and dialysis. Mr. Drake served on the board of directors of Paragon 28, Inc. (NYSE: FNA) a medical device manufacturer, from August 2021 to August 2022. Mr. Drake served as the Chairman of the Board of AtriCure, Inc. (NASDAQ: ATRC) from 2013 to April 2021, as well as a member of the board of directors of Zayo Group Holdings, Inc. (NYSE: ZAYO) from November 2018 to March 2020. He has served on the board of directors of Cordis, a privately held medical device manufacturer, since August 2021. He serves as the Chairperson of the AdvaMed Radiation Therapy Sector as well as a board member for the Medical Device Manufacturers Association (MDMA). Mr. Drake holds a B.S. in Business Administration from Miami University of Ohio.

James F. Dempsey, PhD

Founder and Chief Scientific Officer

Company founder and inventor of the ViewRay technology, Jim Dempsey guides the scientific and technical aspects of the MRIdian system’s development. Dempsey holds a PhD in nuclear chemistry from Washington University. He is a board-certified medical physicist and former associate professor of radiation oncology at the University of Florida.

Rob Fuchs

Chief Human Resources Officer

Rob Fuchs joined ViewRay as Chief Human Resources Officer in October of 2018, bringing more than 25 years of human resource leadership in the medical device, high-tech, telecommunications, and service industries. He most recently served as the Senior Vice President, Global Human Resources Officer for Advanced Energy. Previously, Fuchs served as the Senior Vice President, Global Human Resources at Spectranetics Corporation in Colorado Springs, Colorado. In this role, he led all aspects of human resources. Prior to his role at Spectranetics, he worked for over 13 years at Echostar Communications and DISH Network, public sister companies in Englewood, Colorado. During his tenure there, he held a variety of human resources leadership roles. Mr. Fuchs has a bachelor of science in business and marketing from Ithaca College.

Martin Fuss, MD, PhD

Chief Medical Officer

Dr. Martin Fuss is Chief Medical Officer and the Executive Director of the Clinical Cooperative Think Tank (C2T2) as well as a practicing radiation oncologist and partner in Radiation Oncology Specialists in Tualatin, OR. Dr. Fuss graduated from medical school at the University of Heidelberg, Germany where he also obtained his doctorate degree in human imaging assessing blood flow changes in the brain using functional MRI techniques (DCE-MRI). He underwent his specialty training in radiation oncology at the University of Heidelberg and at the German Cancer Research Center (dkfz). During his residency, he was invited as a research fellow at the Proton Radiation Therapy facility at Loma Linda University Medical Center in Loma Linda, CA. From 2000 to 2006 he was a faculty member at The University of Texas Health Science Center at San Antonio, San Antonio, TX (UTHSCSA). Prior to moving into private practice, he was Professor and Vice Chair of the Department of Radiation Medicine at Oregon Health & Science University (OHSU) from 2006-2013.

Robert McCormack, JD

Chief Legal Officer

Robert McCormack is Chief Legal Officer and joined ViewRay in August 2018. He has worked in the medical device and IT industries since 2008. Prior to that, Mr. McCormack worked in private practice in Denver, Colorado, where he focused on corporate, securities, mergers and acquisitions, and general business matters. Mr. McCormack holds a JD from the University of Denver, College of Law and a BS in Finance from Metropolitan State University of Denver.

William P. Burke

Executive Vice President and
Chief Financial Officer

William P. Burke was appointed as our Executive Vice President and Chief Financial Officer in January 2023. Previously, Mr. Burke served as Executive Vice President and Chief Financial Officer for Haemonetics Corporation, a global blood management solutions company, from August 2016 to April 2022 and stayed on in an advisory capacity through June 2022. From July 2014 to July 2016, he served as Chief Integration Officer and Vice President, Integration for Medtronic, plc, a global healthcare products company and was a member of its Executive Committee. In that role, Mr. Burke was responsible for ensuring the successful integration of Medtronic with Covidien plc, a global healthcare company, following its acquisition by Medtronic. Prior to joining Medtronic, he spent more than 20 years in finance and business development leadership roles at Covidien, including Chief Financial Officer for Covidien Europe based in Zurich, Vice President of Corporate Strategy and Portfolio Management and Vice President of Financial Planning and Analysis. Since January 2022 Mr. Burke has served on the board of directors and as audit committee chair of MiroMatrix (Nasdaq: MIRO), a life sciences company and since July 2022, he has served on the board of directors and as audit committee chair of Axogen (Nasdaq: AXGN), a surgical solutions company. Previously, Mr. Burke also held key positions within Tyco Healthcare, including the Financial Controller of Valleylab, Managing Director of the Covidien Group in Switzerland and International Controller. He began his career as an auditor with KPMG. Mr. Burke received a Bachelor of Science degree in Business Administration from Bryant College.

Paul Ziegler, JD

Executive Vice President and
Chief Commercial Officer

Paul Ziegler is Executive Vice President and Chief Commercial Officer at ViewRay, where he is leading the charge to drive adoption of the MRIdian system. With more than 19 years of experience in the medical device space, Ziegler has proven success in commercializing paradigm-changing technologies. As a global, strategic leader, he brings multi-disciplinary experience managing all functional areas including marketing, product innovation, portfolio strategy and go-to-market execution; Ziegler has led complex businesses to deliver superior results across all product lifecycles. Prior to joining ViewRay, he served as Vice President of Sales for TransEnterix, leading commercialization efforts for the surgical robotics platform, Senhance. His experience also includes more than nine years at Intuitive Surgical and roles at CardioVations and Dianon/LabCorp. He learned leadership and discipline in his eight years in the U.S. Navy, holds a B.A. from Norwich University in Northfield, VT and a J.D. from William and Mary in Williamsburg, VA.

Steven Annen

Senior Vice President
Global Marketing

Steven Annen joined ViewRay in 2019 and brings more than 25 years of experience in marketing, product, and business development across the medical device and life sciences space. Before joining ViewRay, Steven was the Vice President of Product Management and Strategy of Invuity, Inc. Prior to Invuity Steven held various leadership roles in marketing and strategy at Grabit, Intuitive Surgical, Veeco Instruments, and Omron. Steven holds a Master’s in Mechanical Engineering from the University of Wisconsin-Madison and a Bachelor’s in Mechanical Engineering from Rutgers University.

Drew Hill

Senior Vice President
Operations and Development

Drew Hill joined ViewRay in 2018 and brings more than 15 years of experience in Operations across the medical device, pharmaceutical, and consumer products space. Prior to joining ViewRay, Drew was the Director of Operations of the Colorado Springs location of Philips Image Guided Therapy, formerly Spectranetics, and prior to Spectranetics Drew held various roles at GSK Vaccines, formerly Novartis Vaccines. Drew holds an MBA and a SM in Chemical Engineering from the Massachusetts Institute of Technology and a BS in Chemical Engineering from the University of Florida.

Adam Podbelski

Senior Vice President
Global Customer Services

Adam Podbelski is Senior Vice President of Global Customer Services at ViewRay, where he and the Global Services leadership team are focused on radically delighting MRIdian customers. With over 20 years of medical device experience that spans product development, program management, commercial execution, and business development, Adam brings a vast background that guides how ViewRay meets its expanding customer base’s needs. Prior to joining ViewRay, Adam held various leadership roles at Philips, Spectranetics, and Medtronic.

Amanda Williams

Senior Vice President
Clinical, Quality, Regulatory

Amanda Williams joined ViewRay in October of 2018 and brings 20 years of experience in the medical device space. She has been in various leadership roles across clinical, quality and regulatory with Philips Image Guided Therapy division, Spectrantics and AGA Medical (now part of Abbott). At Spectranetics, she led teams that completed multiple global, randomized clinical studies. These successfully drove regulatory approvals allowing market access for strategic business initiatives. One of these studies achieved a first of its kind indication for use with the FDA for the U.S. market. She holds a Master of Science in Regulatory from Northeastern University and a Bachelor of Science in Chemistry from the University of Minnesota.

Board of Directors

Daniel Moore
Chairman

Daniel Moore has served as a member of our board of directors and our Chair since February 2018. Mr. Moore has served as Chairman of the Board for medical device company LivaNova, PLC (NASDAQ: LIVN) since September 2015. He served as a member of the board of directors for GI Dynamics, Inc. (ASX: GID), a medical device company from 2014 to 2020. From 2012 to 2019, Mr. Moore served as a member of the board of directors of medical device company, BrainScope. He served as a member of the board of directors of TriVascular (NASDAQ: TRIV), a medical device company, from 2010 to 2016. From 2007 to 2015, Mr. Moore served as Chief Executive Officer as well as a member of the board of directors of Cyberonics, Inc. (NASDAQ: CYBX), a medical device company. From 1989 to 2007, Mr. Moore held various positions in sales, marketing, and senior management for Boston Scientific Corporation (NYSE: BSX). From 2009 to 2016, Mr. Moore was a member of the board of directors of the Medical Device Manufacturers Association (MDMA), serving as Chair from 2012 to 2014. He was a member of the board of directors of the Medical Device Innovation Consortium (MDIC) from 2012 to 2014. Mr. Moore has served on the board of the Epilepsy Foundation of America since 2014. He holds a B.A. from Harvard University, and an M.B.A. from Boston University.

Caley Castelein, MD

Caley Castelein, M.D. has served as a member of our board of directors since January 2008. Since March 2006, he has served as a Managing Director and founder of Kearny Venture Partners, L.P., a healthcare venture capital fund. Additionally, he founded KVP Capital, L.P. in 2013 and manages the fund which invests in small and mid-cap healthcare companies. Since February 2017, Dr. Castelein has served as a member of the board of directors of Aerpio Therapeutics, Inc. (NASDAQ: ARPO), a biopharmaceutical company, which merged with Aadi Bioscience, Inc. (NASDAQ: AADI) in August 2021 where he now serves as Chair. He served as a member of the board of directors for Boreal Genomics, Inc., a diagnostics company, from October 2010 until its successful sale in September 2021. He has served as a director at NewBridge Pharmaceuticals FZ, LLC, a specialty therapeutics company, since March 2015. Dr. Castelein served as a member of the board of directors for Waterstone Pharmaceuticals, Inc., a pharmaceutical company from March 2015 to March 2018; AliveCor, Inc., a medical device company from April 2015 to March 2020; Wellpartner, Inc., a pharmaceutical distribution solutions company, from March 2015 to November 2017; and Neos Therapeutics, Inc. (NASDAQ: NEOS), a pharmaceutical company from March 2015 to July 2015. He holds an A.B. from Harvard College and an M.D. from the University of California, San Francisco. We believe Dr. Castelein is qualified to serve on our board of directors based on his extensive investment experience in the healthcare industry

Scott Drake

B. Kristine Johnson

B. Kristine Johnson has served as a member of our board of directors since April 2020. Ms. Johnson is currently President and General Partner of Affinity Capital Management, a venture capital firm, since 2000. She has served as member of the board of directors of AtriCure, Inc. (NASDAQ: ATRC), a medical device company, since March 2017, and as Chairperson of the board since April 2021. Ms. Johnson has served as a member of the board of directors of ClearPoint Neuro (NASDAQ: CLPT), a medical device company, since August 2019. She served as a member of the board of directors of Piper Sandler, an investment banking firm, from 2003 to 2019. Ms. Johnson served as a member of the board of directors of The Spectranetics Corporation (NASDAQ: SPNC), a medical device company, from 2012 to 2017. She held various executive leadership positions at Medtronic (NYSE: MDT) from 1982 to 1999. Ms. Johnson serves as a member of the board of directors of the University of Minnesota Foundation Investment Advisors. She holds a B.A. from St. Olaf College.

Karen N. Prange

Karen N. Prange has served as a member of the Board since June 2021. She has served as a member of the board of directors of Cantel Medical (NYSE: CMD), a medical equipment company, since October 2019 until its sale to Steris Corp in June 2021. Ms. Prange has served as a member of the board of directors of Atricure (NASDAQ: ATRC), a medical device company, since December 2019. She has served as a member of the board of directors of Nevro (NASDAQ: NVRO), a medical device company, since December 2019. Ms. Prange has served as a member of the board of directors of WS Audiology, a hearing aid manufacturer, since March 2020. Ms. Prange has served on the board of Embecta (NASDAQ: EMBC since April 2022. She has served as Strategic Advisor to Nuvo Group, LLC, a medical device company, since September of 2019 and Industrial Advisor to EQT Group, a global investment organization, since March 2020. From May 2016 to April 2018, Ms. Prange was Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein as well as a member of the Executive Committee. She served as Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business from 2012 to 2016. From 1995 to 2012, Ms. Prange held various roles of increasing leadership at Johnson & Johnson Company (NYSE: JNJ), most recently as General Manager of the Micrus Endovascular and Codman Neurovascular businesses. She holds a B.S. in Business Administration from the University of Florida. We believe Ms. Prange is qualified to serve on the Board based on her other public medical device board service and her extensive experience in commercial, operational, and strategic leadership roles in healthcare companies.

Brian K. Roberts

Brian K. Roberts has served as a member of our board of directors since December 2015. Since September 2020, Mr. Roberts has served as President and Chief Executive Officer of Tarveda Therapeutics, Inc., a biopharmaceutical company, where he also served as Chief Financial Officer from January 2018 to September 2020. From July 2016 to April 2020, he served as a member of the board of directors for Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company. Mr. Roberts served as Chief Operating and Financial Officer at Avedro, Inc., a pharmaceutical and medical device company, from January 2015 to October 2016. He served as Chief Financial Officer at Insulet Corporation (NASDAQ: PODD), also a medical device company, from 2009 to 2014. Mr. Roberts served as Chief Financial Officer at Jingle Networks, Inc., an advertising and technology solutions company, from September 2007 to December 2008. From 2001 to 2007, he held various leadership roles, including serving as Chief Financial Officer of Digitas, Inc. (NASDAQ: DTAS), (a/k/a DigitasLBi, Inc.), a marketing and technology agency. Mr. Roberts served as Vice President of Finance at Idiom Technologies, Inc., a provider of globalization management, from 2000 to 2001. From 1997 to 1999, he served as U.S. Controller of The Monitor Group, a consulting firm. Mr. Roberts served as an Auditor with Ernst & Young LLP from 1993 to 1997. He holds a B.S. from Boston College.

Susan Schnabel

Susan C. Schnabel has served as a member of the Board since March 2022. Ms. Schnabel is a founder and has served as the Co-Managing Partner of aPriori Capital Partners, a private equity investment firm, since April 2014. She has served on the board of directors of Altice USA (NYSE: ATUS), a broadband communication and video service provider, since July 2021. Ms. Schnabel has served on the board of directors of Kayne Anderson BDC, a private management investment company, since September 2020. Ms. Schnabel served on the board of directors of Versum Materials, Inc. (NYSE: VSM), a technology driven semiconductor materials supplier, from October 2016 to October 2019. Ms. Schnabel has served on numerous other private company boards for the past twenty years. Ms. Schnabel has served on the Cornell University Board of Trustees since July 2019. She has served on the California Institute of Technology Investment Committee since May 2017. Ms. Schnabel has served on the Board of Directors of the US Olympic & Paralympic Foundation since January 2016. She served on the Harvard Business School Alumni Advisory Board from September 2014 to June 2019. Ms. Schnabel holds a B.S. from Cornell University and a M.B.A. from Harvard Business School. Ms. Schnabel was appointed to the board pursuant to a Cooperation Agreement entered into between the Company and Hudson Executive Capital LP and certain of its affiliates (“Hudson”) on March 8, 2022. We believe Ms. Schnabel is qualified to serve on the Board based on her extensive capital markets and investment banking experience, as well as her deep executive and board leadership experience.

Phil Spencer

Phillip Spencer has served as a member of our board of directors since February 2021. He has served as President and Chief Executive Officer and as a member of the board of directors of MBI (Mega-Broadband Investments), a private cable and communications company, since 2018. Mr. Spencer served as Chief Executive Officer of Rural Broadband Investments from 2011 to 2017. He has served as a member of the board of directors of Halftime Institute, a leadership organization, since October 2020. From August 2015 to August 2018, Mr. Spencer served as a member of the board of directors of the Truman Medical Foundation, a non-profit medical provider that serves as the public health system for residents of Jackson County and Kansas City, Missouri. He holds a B.S. from Marquette University.

Gail Wilensky, PhD

Gail Wilensky, Ph.D. Dr. Wilensky has served as a member of our board of directors since July 2019. She has served as a member of the board of directors of UnitedHealth Group, Inc. (NYSE: UNH), a health and well-being services company, since 1993. Dr. Wilensky has served as a member of the board of directors of Quest Diagnostics, Inc. (NYSE: DGX), a diagnostic testing and information company, since 1997. She has served as a Senior Fellow at Project HOPE, an international non-profit health foundation, since 1993. Dr. Wilensky has served in the U.S. Department of Defense as President and Chair, Health Care Advisory Subcommittee from 2008 to 2009, and from 2006 to 2008 as Co-Chair, Task Force on the Future of Military Health. She served as Co-Chair and Presidential Appointee of the Task Force to Improve Healthcare Delivery for the Nation’s Veterans from 2001 to 2003. From 1997 to 2001, Dr. Wilensky served as Chair of the Medicare Payment Advisory Committee. She served as Chair of the Physician Payment Review Commission from 1995 to 1997. From March 1992 to January 1993, Dr. Wilensky served as Deputy Assistant to the President for Policy Development. She served as Administrator of the Health Care Financing Administration (now known as the Centers for Medicare and Medicaid Services) directing the Medicaid and Medicare programs for the United States from 1990 to 1992. Dr. Wilensky serves on the Board of Regents of the Uniformed Services University of the Health Sciences (USUHS) and the Geisinger Health System Foundation and is an elected member of the National Academy of Medicine. She holds a B.A., M.A., and Ph.D. from the University of Michigan.

Medical Advisory Board

Dr. Stefanie Corradini

LMU Klinikum
Munich, Germany

Dr. James Good

GenesisCare Oxford
England, UK

Dr. Enis Özyar

Acibadem Maslak Hospital
Istanbul, Turkey

Leadership

Meet Our Team

Scott Drake

James F. Dempsey, PhD

Rob Fuchs

Martin Fuss, MD, PhD

Robert McCormack, JD

William P. Burke

Paul Ziegler, JD

Steven Annen

Drew Hill

Adam Podbelski

Amanda Williams

Board of Directors

Daniel MooreChairman

Caley Castelein, MD

Scott Drake

B. Kristine Johnson

Karen N. Prange

Brian K. Roberts

Medical Advisory Board

Dr. Stefanie Corradini

Dr. James Good

Dr. Enis Özyar

Daniel Moore
Chairman